AnaptysBio Names Thomas Smart as CEO >ANAB
AnaptysBio Names Thomas Smart as CEO >ANAB
Dow JonesApr 24 09:01 ET
Express News | Actym Therapeutics Appoints Thomas Smart as CEO
Moomoo 24/7Apr 24 09:00 ET
Express News | AnaptysBio Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $47
Moomoo 24/7Apr 16 07:33 ET
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
The Motley FoolApr 12 19:00 ET
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
BenzingaApr 11 13:33 ET
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose sharply during Thursday's session. Enliven Therapeutics an
BenzingaApr 11 10:01 ET
AnaptysBio Initiated at Overweight by Wells Fargo
AnaptysBio Initiated at Overweight by Wells Fargo
Dow JonesApr 11 09:56 ET
Express News | AnaptysBio Inc : Wells Fargo Initiates Coverage With Overweight Rating ; Target Price $56
Moomoo 24/7Apr 11 06:24 ET
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
Yahoo FinanceApr 9 14:40 ET
Unveiling 4 Analyst Insights On AnaptysBio
In the preceding three months, 4 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of perspectives from bullish to bearish.In the table below, you'll find a summary
BenzingaApr 1 15:01 ET
AnaptysBio Is Maintained at Neutral by JP Morgan
AnaptysBio Is Maintained at Neutral by JP Morgan
Dow JonesApr 1 10:16 ET
Express News | JP Morgan Maintains Neutral on AnaptysBio, Lowers Price Target to $28
Moomoo 24/7Apr 1 10:06 ET
PLAB, SMTC and WOOF Are Among After Hour Movers
Seeking AlphaMar 28 16:52 ET
This AnaptysBio Insider Reduced Their Stake By 27%
Viewing insider transactions for AnaptysBio, Inc.'s (NASDAQ:ANAB ) over the last year, we see that insiders were net sellers. This means that a larger number of shares were sold by insiders in relatio
Simply Wall StMar 28 08:32 ET
WPRT, FIVN and FATE Are Among After Hour Movers
Seeking AlphaMar 25 17:15 ET
Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB)
TipRanksMar 18 07:45 ET
Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts
Yahoo FinanceMar 18 06:32 ET
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's Is How to Trade
Yahoo FinanceMar 14 09:55 ET
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Monday, AnaptysBio Inc (NASDAQ:ANAB) reported a fourth-quarter 2023 EPS of $(1.59), slightly better than the consensus of $(1.60).The company reported sales of $9.01 million, surpassing the consensus
BenzingaMar 12 14:48 ET
Express News | AnaptysBio Shares Are Trading Higher After Wedbush Upgraded the Stock From Neutral to Outperform
Moomoo 24/7Mar 12 12:19 ET
No Data
No Data